Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

EIGER BIOPHARMACEUTICALS, INC.

(EIGR)
  Report
Delayed Nasdaq  -  04:00 2022-12-09 pm EST
1.280 USD   +9.40%
12/09Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus Achieved Statistical Significance Against Placebo in Composite Primary Endpoint
AQ
12/08Sector Update: Healthcare Stocks Adding to Earlier Gains Near Close Thursday
MT
12/08Sector Update: Healthcare
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Eiger Shares Fall After Plans Dropped for Covid-19 Treatment FDA Emergency Use Authorization

10/05/2022 | 06:54am EST

By Sabela Ojea


Shares of Eiger BioPharmaceuticals Inc. fell 20% early Wednesday after the company said that it won't submit a Food and Drug Administration emergency use authorization application for a Covid-19 treatment.

In premarket trading, the stock was at $5.89, down from its close of $7.39 on Tuesday.

The biopharmaceutical company, which mainly develops and commercializes therapies for the hepatitis delta virus, said that the change in plans has been driven by feedback received from the FDA on the use of the peginterferon lambda interferon in patients with mild-to-moderate Covid-19.

The FDA concluded that any authorization request based on Eiger's data was unlikely to meet the statutory criteria for issuance of emergency use authorization in the current context of the pandemic, the company said.

Eiger is now assessing which steps to take in the U.S., the company said, adding that the FDA has asked it to consider requesting an end-of-Phase 2 meeting to discuss a company-sponsored pivotal trial that could support an eventual biologics license application.


Write to Sabela Ojea at sabela.ojea@wsj.com


(END) Dow Jones Newswires

10-05-22 0854ET

All news about EIGER BIOPHARMACEUTICALS, INC.
12/09Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hep..
AQ
12/08Sector Update: Healthcare Stocks Adding to Earlier Gains Near Close Thursd..
MT
12/08Sector Update: Healthcare
MT
12/08Top Midday Decliners
MT
12/08Eiger BioPharmaceuticals Reports Data From Late-Stage Trial of Hepatitis Treatment; Sto..
MT
12/08Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 D-LIVR Study Result..
AQ
12/08Eiger BioPharmaceuticals Phase 3 Lonafarnib-Based Treatments Achieve Statistical Signif..
MT
12/08Transcript : Eiger BioPharmaceuticals, Inc. - Special Call
CI
12/08Eiger Biopharmaceuticals, Inc. : Other Events, Financial Statements and Exhibits (form 8-K..
AQ
12/08Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hep..
PR
More news
Analyst Recommendations on EIGER BIOPHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 15,1 M - -
Net income 2022 -96,3 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,57x
Yield 2022 -
Capitalization 56,4 M 56,4 M -
Capi. / Sales 2022 3,73x
Capi. / Sales 2023 2,65x
Nbr of Employees 54
Free-Float 94,8%
Chart EIGER BIOPHARMACEUTICALS, INC.
Duration : Period :
Eiger BioPharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EIGER BIOPHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1,28 $
Average target price 9,25 $
Spread / Average Target 623%
EPS Revisions
Managers and Directors
David A. Cory President, Chief Executive Officer & Director
Sriram Ryali Chief Financial Officer
Thomas John Dietz Independent Chairman
Ingrid C. Choong Senior Vice President-Clinical Development
Colin Hislop Senior VP-Clinical & Development Operations
Sector and Competitors
1st jan.Capi. (M$)
EIGER BIOPHARMACEUTICALS, INC.-77.46%56
MODERNA, INC.-27.28%68 134
IQVIA HOLDINGS INC.-26.09%38 732
LONZA GROUP AG-39.96%36 385
ALNYLAM PHARMACEUTICALS, INC.40.35%28 460
SEAGEN INC.-19.79%23 022